Issue
Date Log
Copyright (c) 2026 Abdulaziz Hadi Ibrahim Tawhari, Salman Abdulrahman Alotaibi, Ibrahim Abdullah Nasser Mobarki, Muneera Abdulrhman Alotaibi, Ahmed Muslih Khlaif Alrashidi, Ahlam Mohammad Almalki, Mutlaq Rahim Mutlaq Alhafi, Faizah Ali Hadadi, Elham Kamil Alanazi, Sitah Khairallah Mubarak, Awatif Ali Jurbuh Ageeli, Samiyah Dhaifallah Fahad Alotaibi, Waleed Abdullah Albusairi

This work is licensed under a Creative Commons Attribution 4.0 International License.
Medication-Related Post-COVID-19 Osteonecrosis of the Jaw: An Interprofessional Approach to Prevention, Diagnosis, and Management.
Corresponding Author(s) : Abdulaziz Hadi Ibrahim Tawhari
Saudi Journal of Medicine and Public Health,
Vol. 3 No. 1 (2026)
Abstract
Background: Post-COVID-19 osteonecrosis of the jaw (PC-ONJ) has emerged as an uncommon but clinically significant complication reported after SARS-CoV-2 infection. Its development may involve multiple interacting factors, including corticosteroid exposure, diabetes mellitus, immunosuppression, vascular injury, and secondary infections. COVID-associated mucormycosis (CAM) represents a particularly aggressive form that can cause extensive maxillofacial destruction and life-threatening complications.
Aim: This review examines the clinical presentation, risk factors, diagnostic challenges, and current management strategies for PC-ONJ, with particular attention to differentiating non-fungal osteonecrotic lesions from CAM.
Methods: A narrative review of the relevant literature was conducted to summarize reported clinical manifestations, proposed pathogenic mechanisms, diagnostic approaches, treatment options, and outcomes. Evidence concerning medical and surgical interventions, adjunctive therapies, and preventive measures was also considered.
Results: PC-ONJ presents with variable manifestations, including persistent facial pain, swelling, tooth mobility, exposed bone, fistulas, and delayed wound healing. The maxilla is frequently affected, and lesions may extend into the paranasal sinuses and adjacent structures. Diagnosis remains challenging because clinical and radiological findings overlap with osteomyelitis, medication-related osteonecrosis, osteoradionecrosis, malignancy, and invasive fungal infections. Management depends on the underlying pathology and disease extent. CAM requires prompt systemic antifungal therapy and surgical debridement, whereas non-fungal lesions may respond to conservative measures, antibiotics when indicated, and appropriate surgery.
Conclusion: Early recognition, accurate etiological assessment, metabolic control, and multidisciplinary management are essential to improve outcomes and reduce complications.
Keywords
Download Citation
Endnote/Zotero/Mendeley (RIS)BibTeX
- 1. Kohansal Vajari, M.; Shirin, M.; Pourbagheri-Sigaroodi, A.; Akbari, M.E.; Abolghasemi, H.; Bashash, D. COVID-19-related coagulopathy: A review of pathophysiology and pharmaceutical management. Cell Biol. Int. 2021, 45, 1832–1850.
- 2. Conway, E.M.; Mackman, N.; Warren, R.Q.; Wolberg, A.S.; Mosnier, L.O.; Campbell, R.A.; Gralinski, L.E.; Rondina, M.T.; van de Veerdonk, F.L.; Hoffmeister, K.M.; et al. Understanding COVID-19-associated coagulopathy. Nat. Rev. Immunol. 2022, 22, 639–649.
- 3. Bobamuratova, D.; Boymuradov, S.; Kurbanov, Y. Complications in the maxillofacial region in patients with COVID-19. J. Neurol. Sci. 2021, 429, 119784.
- 4. Abdullah, B.; Museedi, O.; Allawi, N.; Ismael, F.J.; Warnakulasuriya, S. Impact of COVID-19 on the prevalence of oral and maxillofacial disorders: A retrospective cohort study. Sci. Prog. 2025, 108, 368504251326453.
- 5. Vardas, E.; Adamo, D.; Canfora, F.; Kouri, M.; Delli, K.; Mignogna, M.D.; Nikitakis, N. Impact of COVID-19 disease on the development of osteomyelitis of jaws: A systematic review. J. Clin. Med. 2024, 13, 4290.
- 6. Khan, M.A.; Rahman, T.; Rahman, S.A.; Hashmi, G.S.; Ansari, M.K.; Danish, M.; Arman, M.; Ahmad, R.; Ahmad, W. Is post-COVID osteonecrosis of jaw (PCONJ) masquerading as osteomyelitis? A largest unicentric report of 13 cases. Adv. Oral Maxillofac. Surg. 2023, 11, 100435.
- 7. Al-Mahalawy, H.; El-Mahallawy, Y.; Dessoky, N.Y.; Ibrahim, S.; Amer, H.; Ayad, H.M.; El Sherif, H.M.; Shabaan, A.A. Post-COVID-19 related osteonecrosis of the jaw (PC-RONJ): An alarming morbidity in COVID-19 surviving patients. BMC Infect. Dis. 2022, 22, 544.
- 8. Yfanti, Z.; Tetradis, S.; Nikitakis, N.G.; Alexiou, K.E.; Makris, N.; Angelopoulos, C.; Tsiklakis, K. Radiologic findings of osteonecrosis, osteoradionecrosis, osteomyelitis and jaw metastatic disease with cone beam CT. Eur. J. Radiol. 2023, 165, 110916.
- 9. Subramaniam, S.; Kothari, H.; Bosmann, M. Tissue factor in COVID-19-associated coagulopathy. Thromb. Res. 2022, 220, 35–47.
- 10. Mañón, V.A.; Balandran, S.; Young, S.; Wong, M.; Melville, J.C. COVID-associated avascular necrosis of the maxilla—A rare, new side effect of COVID-19. J. Oral Maxillofac. Surg. 2022, 80, 1254–1259.
- 11. Sourani, A.; Kalantari, F.; El-Rabbany, M.; Shahmoradi, M.; Haridas, A.; Vahdat, N.; Mirza, S.; Sourani, A.; Foroughi, M.; Baradaran Mahdavi, S. COVID-19 and jaw osteonecrosis: A systematic review on clinical presentations and treatment outcomes. Curr. Probl. Surg. 2025, 73, 101897.
- 12. Cheng, E.Y.; Mirzaei, A.; Sugano, N.; Hernigou, P.; Jones, L.C.; Koo, K.-H.; Drescher, W.R.; Cui, Q.; Sierra, R.J.; Goodman, S.B.; et al. Osteonecrosis: A more appropriate term than avascular necrosis—Pathophysiologic rationale. J. Arthroplast. 2025, 40, 2729–2736.
- 13. Lončar Brzak, B.; Horvat Aleksijević, L.; Vindiš, E.; Kordić, I.; Granić, M.; Vidović Juras, D.; Andabak Rogulj, A. Osteonecrosis of the jaw. Dent. J. 2023, 11, 23.
- 14. Tetradis, S.; Allen, M.R.; Ruggiero, S.L. Pathophysiology of medication-related osteonecrosis of the jaw—A minireview. JBMR Plus 2023, 7, e10785.
- 15. Hines, J.T.; Jo, W.-L.; Cui, Q.; Mont, M.A.; Koo, K.-H.; Cheng, E.Y.; Goodman, S.B.; Ha, Y.-C.; Hernigou, P.; Jones, L.C.; et al. Osteonecrosis of the femoral head: An updated review of ARCO on pathogenesis, staging and treatment. J. Korean Med. Sci. 2021, 36, e177. [
- 16. Ruggiero, S.L.; Dodson, T.B.; Aghaloo, T.; Carlson, E.R.; Ward, B.B.; Kademani, D. American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the jaws—2022 update. J. Oral Maxillofac. Surg. 2022, 80, 920–943.
- 17. Hakobyan, K.; Poghosyan, Y. “Krokodil” drug-related osteonecrosis of midface: A case series. J. Craniomaxillofac. Surg. 2019, 47, 1918–1921.
- 18. Sharma, S.; Shankar, R.; Ravi Kiran, B.S.; Breh, R.; Sarangi, S.; Kumar Upadhyay, A. A narrative review of osteonecrosis of the jaw: What a clinician should know. Cureus 2023, 15, e51183.
- 19. Singh, G.; Campos, A.; Guan, H. Medication-Related Osteonecrosis of the Jaw. 2009. Available online: https://radiopaedia.org/articles/medication-related-osteonecrosis-of-the-jaw?lang=us
- 20. Thomas, J.G.; Ouanounou, A. Medication-related osteonecrosis of the jaw: A narrative review of risk factors, diagnosis, and management. Front. Oral Maxillofac. Med. 2023, 5, 31.
- 21. Havndrup-Pedersen, C.; Møller Andersen, S.W.; Nyberg, J.; Kofod, T. New classification system for osteoradionecrosis of the jaws—An integrative review. Br. J. Oral Maxillofac. Surg. 2025, 63, 707–713.
- 22. Bolchis, V.; Alexa, I.; Toderas, N.A.; Dumitrescu, R.; Sava-Rosianu, R.; Balean, O.; Alexa, V.T.; Popescu, S.; Jumanca, D.; Galuscan, A.; et al. Associations between lifestyle factors, oral health behaviors, and glycemic control in type 2 diabetic patients. J. Clin. Med. 2025, 14, 450.
- 23. Oliver-Puigdomènech, C.; González-Navarro, B.; Polis-Yanes, C.; Estrugo-Devesa, A.; Jané-Salas, E.; López-López, J. Incidence rate of metastases in the oral cavity: A review of all metastatic lesions in the oral cavity. Med. Oral Patol. Oral Cir. Bucal 2021, 26, e619–e625.
- 24. Ruggiero, S.L.; Dodson, T.B.; Aghaloo, T.; Carlson, E.R.; Ward, B.B.; Kademani, D. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J. Oral Maxillofac. Surg. 2014, 72, 1938–1956.
- 25. Trimarchi, M.; Bertazzoni, G.; Bussi, M. Cocaine-induced midline destructive lesions. Rhinology 2014, 52, 104–111.
- 26. Lončar Brzak, B.; Vučičević Boras, V.; Kotarac Knežević, A.; Sušić, M.; Seiwerth, S.; Gabrić, D. Idiopathic exposed bone lesions of the jaw. Dent. J. 2019, 7, 55.
- 27. Bansal, H. Medication-related osteonecrosis of the jaw: An update. Natl. J. Maxillofac. Surg. 2022, 13, 5.
- 28. Khan, A.A.; Morrison, A.; Hanley, D.A.; Felsenberg, D.; McCauley, L.K.; O’Ryan, F.; Reid, I.R.; Ruggiero, S.L.; Taguchi, A.; Tetradis, S.; et al. Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus. J. Bone Miner. Res. 2015, 30, 3–23.
- 29. Moreno, A.C.; Watson, E.E.; Humbert-Vidan, L.; Peterson, D.E.; van Dijk, L.V.; Guerrero Urbano, T.; Van den Bosch, L.; Hope, A.J.; Katz, M.S.; Hoebers, F.J.P.; et al. International expert-based consensus definition, classification criteria, and minimum data elements for osteoradionecrosis of the jaw: An interdisciplinary modified Delphi study. Int. J. Radiat. Oncol. Biol. Phys. 2025, 122, 341–354.
- 30. Peckham, H.; de Gruijter, N.M.; Raine, C.; Radziszewska, A.; Ciurtin, C.; Wedderburn, L.R.; Rosser, E.C.; Webb, K.; Deakin, C.T. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat. Commun. 2020, 11, 6317.
- 31. Pai, V.; Sansi, R.; Kharche, R.; Bandili, S.C.; Pai, B. Rhino-orbito-cerebral mucormycosis: Pictorial review. Insights Imaging 2021, 12, 167.
- 32. Justine, D.; Bhalla, A.S.; Manchanda, S.; Bhutia, O.; Roychoudhury, A. Osteomyelitis of the jaw bones and its mimics: Resolving the diagnostic enigma. Indian J. Radiol. Imaging 2025, 35, 361–373.
- 33. Said Ahmed, W.M.; Elsherbini, A.M.; Elsherbiny, N.M.; El-Sherbiny, M.; Ramzy, N.I.; Arafa, A.F. Maxillary mucormycosis osteomyelitis in post COVID-19 patients: A series of fourteen cases. Diagnostics 2021, 11, 2050.
- 34. Yasir, M.; Goyal, A.; Sonthalia, S. Corticosteroid Adverse Effects. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2026. Available online: https://www.ncbi.nlm.nih.gov/books/NBK531462/
- 35. Amaral, T.F.d.; Coutinho, N.M.d.S.R.; Fuentefria, R.d.N.; Fuentefria, A.M.; Machado, G.d.R.M. Corticosteroid therapy associated with COVID-19: An ally or a risk factor for the establishment of secondary fungal co-infections? Clin. Biomed. Res. 2023, 42, 369–377.
- 36. RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 2021, 384, 693–704.
- 37. Wang, A.S.; Armstrong, E.J.; Armstrong, A.W. Corticosteroids and wound healing: Clinical considerations in the perioperative period. Am. J. Surg. 2013, 206, 410–417.
- 38. Gupta, A.; Kayarat, B.; Gupta, N. COVID-19 associated mucormycosis (CAM). Saudi J. Anaesth. 2023, 17, 58–64.
- 39. Liu, L.H.; Zhang, Q.Y.; Sun, W.; Li, Z.R.; Gao, F.Q. Corticosteroid-induced osteonecrosis of the femoral head. Chin. Med. J. 2017, 130, 2601–2607.
- 40. Mantovani, A.; Byrne, C.D.; Zheng, M.H.; Targher, G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. Nutr. Metab. Cardiovasc. Dis. 2020, 30, 1236–1248.
- 41. Hoenigl, M.; Seidel, D.; Carvalho, A.; Rudramurthy, S.M.; Arastehfar, A.; Gangneux, J.-P.; Nasir, N.; Bonifaz, A.; Araiza, J.; Klimko, N.; et al. The emergence of COVID-19 associated mucormycosis: A review of cases from 18 countries. Lancet Microbe 2022, 3, e543–e552.
- 42. Ibrahim, A.S.; Spellberg, B.; Walsh, T.J.; Kontoyiannis, D.P. Pathogenesis of mucormycosis. Clin. Infect. Dis. 2012, 54, S16–S22.
- 43. Pal, R.; Singh, B.; Bhadada, S.K.; Banerjee, M.; Bhogal, R.S.; Hage, N.; Kumar, A. COVID-19-associated mucormycosis: An updated systematic review of literature. Mycoses 2021, 64, 1452–1459.
- 44. Rao, V.U.S.; Arakeri, G.; Madikeri, G.; Shah, A.; Oeppen, R.S.; Brennan, P.A. COVID-19 associated mucormycosis (CAM) in India: A formidable challenge. Br. J. Oral Maxillofac. Surg. 2021, 59, 1095–1098.
- 45. Ackermann, M.; Verleden, S.E.; Kuehnel, M.; Haverich, A.; Welte, T.; Laenger, F.; Vanstapel, A.; Werlein, C.; Stark, H.; Tzankov, A.; et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med. 2020, 383, 120–128.
- 46. Ghanbari, E.P.; Jakobs, K.; Puccini, M.; Reinshagen, L.; Friebel, J.; Haghikia, A.; Kränkel, N.; Landmesser, U.; Rauch-Kröhner, U. The role of NETosis and complement activation in COVID-19-associated coagulopathies. Biomedicines 2023, 11, 1371.
- 47. Perico, L.; Morigi, M.; Galbusera, M.; Pezzotta, A.; Gastoldi, S.; Imberti, B.; Perna, A.; Ruggenenti, P.; Donadelli, R.; Benigni, A.; et al. SARS-CoV-2 spike protein 1 activates microvascular endothelial cells and complement system leading to platelet aggregation. Front. Immunol. 2022, 13, 827146.
- 48. Yamaoka-Tojo, M. Endothelial glycocalyx damage as a systemic inflammatory microvascular endotheliopathy in COVID-19. Biomed. J. 2020, 43, 399–413.
- 49. Song, J.; Li, Y.; Huang, X.; Chen, Z.; Li, Y.; Liu, C.; Chen, Z.; Duan, X. Systematic analysis of ACE2 and TMPRSS2 expression in salivary glands reveals underlying transmission mechanism caused by SARS-CoV-2. J. Med. Virol. 2020, 92, 2556–2566.
- 50. Xu, S.; Ilyas, I.; Weng, J. Endothelial dysfunction in COVID-19: An overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol. Sin. 2023, 44, 695–709.
- 51. Daher, J. Endothelial dysfunction and COVID-19 (Review). Biomed. Rep. 2021, 15, 102.
- 52. Lin, E.-C.; Chiang, Y.-C.; Lin, H.-Y.; Tseng, S.-Y.; Hsieh, Y.-T.; Shieh, J.-A.; Huang, Y.-H.; Tsai, H.-T.; Feng, S.-W.; Peng, T.-Y.; et al. Unraveling the link between periodontitis and coronavirus disease 2019: Exploring pathogenic pathways and clinical implications. Biomedicines 2023, 11, 2789.
- 53. Qi, X.; Northridge, M.E.; Hu, M.; Wu, B. Oral health conditions and COVID-19: A systematic review and meta-analysis of the current evidence. Aging Health Res. 2022, 2, 100064.
- 54. Huang, N.; Pérez, P.; Kato, T.; Mikami, Y.; Okuda, K.; Gilmore, R.C.; Domínguez Conde, C.; Gasmi, B.; Stein, S.; Beach, M.; et al. SARS-CoV-2 infection of the oral cavity and saliva. Nat. Med. 2021, 27, 892–903.
- 55. Alahdal, M.; Elkord, E. Exhaustion and over-activation of immune cells in COVID-19: Challenges and therapeutic opportunities. Clin. Immunol. 2022, 245, 109177.
- 56. Gustine, J.N.; Jones, D. Immunopathology of hyperinflammation in COVID-19. Am. J. Pathol. 2021, 191, 4–17.
- 57. Chen, Z.; Wherry, E.J. T cell responses in patients with COVID-19. Nat. Rev. Immunol. 2020, 20, 529–536.
- 58. Zhang, S.; Asquith, B.; Szydlo, R.; Tregoning, J.S.; Pollock, K.M. Peripheral T cell lymphopenia in COVID-19: Potential mechanisms and impact. Immunother. Adv. 2021, 1, ltab015.
- 59. Ronchetti, S.; Ricci, E.; Migliorati, G.; Gentili, M.; Riccardi, C. How glucocorticoids affect the neutrophil life. Int. J. Mol. Sci. 2018, 19, 4090.
- 60. Ibrahim, A.S. Host cell invasion in mucormycosis: Role of iron. Curr. Opin. Microbiol. 2011, 14, 406–411.
- 61. Arora, U.; Priyadarshi, M.; Katiyar, V.; Soneja, M.; Garg, P.; Gupta, I.; Bharadiya, V.; Berry, P.; Ghosh, T.; Patel, L.; et al. Risk factors for coronavirus disease-associated mucormycosis. J. Infect. 2022, 84, 383–390.
- 62. Bhanuprasad, K.; Manesh, A.; Devasagayam, E.; Varghese, L.; Cherian, L.M.; Kurien, R.; Karthik, R.; Deodhar, D.; Vanjare, H.; Peter, J.; et al. Risk factors associated with the mucormycosis epidemic during the COVID-19 pandemic. Int. J. Infect. Dis. 2021, 111, 267–270
- 63. Hernández, J.L.; Buckley, C.J. Mucormycosis. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2025. Available online: https://www.ncbi.nlm.nih.gov/books/NBK544364/
- 64. Jeican, I.I.; Horhat, D.I.; Dumitru, M.; Florea, A.; Barbu-Tudoran, L.; Gheban, B.-A.; Anton, V.; Toader, C.; Aluaș, M.; Siserman, C.V.; et al. COVID-19-associated rhino-orbital mucormycosis: Histological and electron microscopy characteristics. Diagnostics 2024, 14, 429.
- 65. Domán, M.; Bányai, K. COVID-19-associated fungal infections: An urgent need for alternative therapeutic approach? Front. Microbiol. 2022, 13, 919501.
- 66. Fakhar, M.; Zakariaei, Z.; Sharifpour, A.; Banimostafavi, E.S.; Pourmousa, R.; Soleymani, M.; Ghasemi, M. Post-COVID-19 maxillary osteonecrosis and floating maxillary teeth due to mucormycosis in two uncontrolled diabetic patients. Clin. Case Rep. 2022, 10, e05502.
- 67. Kang, Y.-H.; Lee, S.-S.; Aung, M.T.Z.; Kang, J.-H.; Kim, J.-E.; Huh, K.-H.; Heo, M.-S. Mucormycosis-related osteomyelitis of the maxilla in a post-COVID-19 patient. Imaging Sci. Dent. 2022, 52, 435.
- 68. Motevasseli, S.; Nazarpour, A.; Dalili Kajan, Z.; Yousefi, Z.; Khosravifard, N.; Kashi, F.; Roudbari, N. Post-COVID mucormycosis osteomyelitis and its imaging manifestations in the north of Iran: Case series. Oral Radiol. 2024, 40, 69–80.
- 69. Weinstein, R.S. Glucocorticoid-induced osteonecrosis. Endocrine 2012, 41, 183–190.
- 70. Xie, X.H.; Wang, X.L.; Yang, H.L.; Zhao, D.W.; Qin, L. Steroid-associated osteonecrosis: Epidemiology, pathophysiology, animal model, prevention, and potential treatments. J. Orthop. Transl. 2015, 3, 58–70.
- 71. Powell, C.; Chang, C.; Naguwa, S.M.; Cheema, G.; Gershwin, M.E. Steroid-induced osteonecrosis: An analysis of steroid dosing risk. Autoimmun. Rev. 2010, 9, 721–743.
- 72. Zhang, Q.; Lv, J.; Jin, L. Role of coagulopathy in glucocorticoid-induced osteonecrosis of the femoral head. J. Int. Med. Res. 2018, 46, 2141–2148.
- 73. Rhou, Y.J.J.; Hor, A.; Wang, M.; Wu, Y.F.; Jose, S.; Chipps, D.R.; Cheung, N.W. Dexamethasone-induced hyperglycaemia in COVID-19: Glycaemic profile in patients without diabetes and factors associated with hyperglycaemia. Diabetes Res. Clin. Pract. 2022, 194, 110151.
- 74. Hwang, J.L.; Weiss, R.E. Steroid-induced diabetes: A clinical and molecular approach to understanding and treatment. Diabetes Metab. Res. Rev. 2014, 30, 96–102.
- 75. Barker, H.L.; Morrison, D.; Llano, A.; Sainsbury, C.A.R.; Jones, G.C. Practical guide to glucocorticoid-induced hyperglycaemia and diabetes. Diabetes Ther. 2023, 14, 937–945.
- 76. Spampinato, S.F.; Caruso, G.I.; De Pasquale, R.; Sortino, M.A.; Merlo, S. The treatment of impaired wound healing in diabetes: Looking among old drugs. Pharmaceuticals 2020, 13, 60.
- 77. Goulding, N.J.; Euzger, H.S.; Butt, S.K.; Perretti, M. Novel pathways for glucocorticoid effects on neutrophils in chronic inflammation. Inflamm. Res. 1998, 47, 158–165.
- 78. Narazaki, M.; Kishimoto, T. The two-faced cytokine IL-6 in host defense and diseases. Int. J. Mol. Sci. 2018, 19, 3528.
- 79. McElvaney, O.J.; Curley, G.F.; Rose-John, S.; McElvaney, N.G. Interleukin-6: Obstacles to targeting a complex cytokine in critical illness. Lancet Respir. Med. 2021, 9, 643–654.
- 80. The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group.Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19. JAMA 2021, 326, 499.
- 81. Malgie, J.; Schoones, J.W.; Zeegers, M.P.; Pijls, B.G. Decreased mortality and increased side effects in COVID-19 patients treated with IL-6 receptor antagonists: Systematic review and meta-analysis. Sci. Rep. 2021, 11, 21522.
- 82. Roudbary, M.; Kumar, S.; Kumar, A.; Černáková, L.; Nikoomanesh, F.; Rodrigues, C.F. Overview on the prevalence of fungal infections, immune response, and microbiome role in COVID-19 patients. J. Fungi 2021, 7, 720.
- 83. Nambiar, M.; Varma, S.R.; Jaber, M.; Sreelatha, S.V.; Thomas, B.; Nair, A.S. Mycotic infections—Mucormycosis and oral candidiasis associated with COVID-19: A significant and challenging association. J. Oral Microbiol. 2021, 13, 1967699.
- 84. Aliberti, A.; Gasparro, R.; Mignogna, M.; Canfora, F.; Spagnuolo, G.; Sammartino, G.; Coppola, N. Unveiling the oral lesions, dysgeusia and osteonecrosis related to COVID-19: A comprehensive systematic review. J. Clin. Med. 2025, 14, 1267.
- 85. Grillo, R.; Samiei Rad, S.; Alizadeh, O.; Hosseini Zarch, S.H.; Khodashahi, R.; Kazemian, N.; Naclério-Homem, M.G. Two cases of COVID-related osteonecrosis of the jaws: A new and worrying entity is emerging. World J. Plast. Surg. 2024, 13, 96–102.
- 86. Bansal, P.; Goyal, A.; Cusick, A.; Lahan, S.; Dhaliwal, H.S.; Bhyan, P.; Bhattad, P.B.; Aslam, F.; Ranka, S.; Dalia, T.; et al. Hydroxychloroquine: A comprehensive review and its controversial role in coronavirus disease 2019. Ann. Med. 2021, 53, 117–134.
- 87. Ponnaiah, M.; Ganesan, S.; Bhatnagar, T.; Thulasingam, M.; Majella, M.G.; Karuppiah, M.; Rizwan, S.A.; Alexander, A.; Sarkar, S.; Kar, S.S.; et al. Hyperglycemia and steroid use increase the risk of rhino-orbito-cerebral mucormycosis regardless of COVID-19 hospitalization: Case-control study, India. PLoS ONE 2022, 17, e0272042.
- 88. Espi, M.; Koppe, L.; Fouque, D.; Thaunat, O. Chronic kidney disease-associated immune dysfunctions: Impact of protein-bound uremic retention solutes on immune cells. Toxins 2020, 12, 300.
- 89. Syed-Ahmed, M.; Narayanan, M. Immune dysfunction and risk of infection in chronic kidney disease. Adv. Chronic Kidney Dis. 2019, 26, 8–15.
- 90. Portolés, J.; Martín, L.; Broseta, J.J.; Cases, A. Anemia in chronic kidney disease: From pathophysiology and current treatments to future agents. Front. Med. 2021, 8, 642296.
- 91. Badura, K.; Janc, J.; Wąsik, J.; Gnitecki, S.; Skwira, S.; Młynarska, E.; Rysz, J.; Franczyk, B. Anemia of chronic kidney disease—A narrative review of its pathophysiology, diagnosis, and management. Biomedicines 2024, 12, 1191.
- 92. Palit, S.; Kendrick, J. Vascular calcification in chronic kidney disease: Role of disordered mineral metabolism. Curr. Pharm. Des. 2014, 20, 5829–5833.
- 93. Aguilar, A.; Gifre, L.; Ureña-Torres, P.; Carrillo-López, N.; Rodriguez-García, M.; Massó, E.; da Silva, I.; López-Báez, V.; Sánchez-Bayá, M.; Prior-Español, Á.; et al. Pathophysiology of bone disease in chronic kidney disease: From basics to renal osteodystrophy and osteoporosis. Front. Physiol. 2023, 14, 1177829.
- 94. Lafage-Proust, M.H. Bone and chronic kidney disease. Semin. Musculoskelet. Radiol. 2023, 27, 463–470.
- 95. Goel, K.; Dhillon, J.; Yadav, V.; Bhagat, S.; Aggarwal, A. Post-COVID isolated mandibular mucormycosis in a patient with chronic kidney disease: A case report. Indian J. Otolaryngol. Head Neck Surg. 2023, 75, 2538–2543.
- 96. van Cann, T.; Loyson, T.; Verbiest, A.; Clement, P.M.; Bechter, O.; Willems, L.; Spriet, I.; Coropciuc, R.; Politis, C.; Vandeweyer, R.O.; et al. Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support. Care Cancer 2018, 26, 869–878.
- 97. Bobamuratova, D.T.; Boymuradov, S.A.; Dar-Odeh, N.S.; Kurbanov, Y.K.; Umarov, R.Z. Impact of COVID-19 disease and its treatment on the development of maxillofacial complications. Adv. Oral Maxillofac. Surg. 2021, 4, 100169.
- 98. Dar-Odeh, N.; Bobamuratova, D.T.; Alnazzawi, A.; Babkair, H.; Jambi, S.; Abu-Hammad, A.; Abu-Hammad, O. Jaw-related complications in COVID-19 patients: A systematic review. CRANIO 2024, 42, 630–637.
- 99. Kaboosaya, B.; Damrongsirirat, N.; Koosrivinij, S.; Pimkhaokham, A. Invasive Maxillary Mucormycosis in Post-COVID-19: A Case Report and Review of Literatures. J. Dent. Assoc. Thai. 2024, 74, 108–122.
- 100. Datarkar, A.; Bhawalkar, A.; Shah, V.; Manekar, V.; Gadve, V.; Daware, S.; Walkey, D.; Gioia, F.; Acero, J. Osteomyelitis of the jaw due to mucormycosis after coronavirus disease 2019 infection—A prospective study. Ann. Maxillofac. Surg. 2024, 14, 40–45.
- 101. Vijapur, M.; Kattimani, V.; Varsha, V.; Girish, H.; Kamat, M.; Ram, B. COVID-19 associated mucormycosis (CAM): A single hospital-based study. J. Oral Maxillofac. Pathol. 2022, 26, 147–155.
- 102. Altay, M.A.; Eroğlu, C.N.; Karaca, B.; Doğan, S.U. Post-COVID-19 extensive maxillary actinomycotic osteonecrosis: A rare case report. Akdeniz Diş Hekim. Derg. 2025, 4, 63–69.
- 103. Omranzadeh, A.; Afzalzadeh, M.; Ghodsi, A.; Neshati, H.; Mahdavi Rashed, M. Radiological features of COVID-19-associated mucormycosis: A report of 36 cases along with a literature review. Clin. Case Rep. 2023, 11, e8154.
- 104. Romano, A.; Gasparro, R.; Campana, M.D.; Pinchera, B.; Di Crescenzo, R.M.; Del Guercio, D.; Sarcinella, M.; Tatullo, M.; Sammartino, G. COVID-19 as a critical risk factor for osteonecrosis of the jaw: Diagnostic challenge and surgical treatment. Curr. Probl. Surg. 2024, 61, 101555.
- 105. Rudramurthy, S.M.; Hoenigl, M.; Meis, J.F.; Cornely, O.A.; Muthu, V.; Gangneux, J.P.; Perfect, J.; Chakrabarti, A. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses 2021, 64, 1028–1037.
- 106. Cornely, O.A.; Alastruey-Izquierdo, A.; Arenz, D.; Chen, S.C.A.; Dannaoui, E.; Hochhegger, B.; Hoenigl, M.; Jensen, H.E.; Lagrou, K.; Lewis, R.E.; et al. Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect. Dis. 2019, 19, e405–e421.
- 107. Muthu, V.; Agarwal, R.; Patel, A.; Kathirvel, S.; Abraham, O.C.; Aggarwal, A.N.; Bal, A.; Bhalla, A.S.; Chhajed, P.N.; Chaudhry, D.; et al. Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India. Lancet Infect. Dis. 2022, 22, e240–e253.
- 108. Huynh, D.V.; Nguyen, D.K.; Nguyen, T.V.; Bui, T.V.; Le, C.T. Maxillary osteonecrosis related to post-COVID-19: A report of case series and 6-month follow-up. J. Oral Maxillofac. Surg. Med. Pathol. 2025, 37, 180–187.
- 109. Gaêta-Araujo, H.; Vanderhaeghen, O.; Vasconcelos, K.F.; Coucke, W.; Coropciuc, R.; Politis, C.; Jacobs, R. Osteomyelitis, osteoradionecrosis, or medication-related osteonecrosis of the jaws? Can CBCT enhance radiographic diagnosis? Oral Dis. 2021, 27, 312–319.
- 110. Yasmin, F.; Najeeb, H.; Naeem, A.; Dapke, K.; Phadke, R.; Asghar, M.S.; Shah, S.M.I.; De Berardis, D.; Ullah, I. COVID-19 associated mucormycosis: A systematic review from diagnostic challenges to management. Diseases 2021, 9, 65
- 111. Peterson, D.E.; Koyfman, S.A.; Yarom, N.; Lynggaard, C.D.; Ismaila, N.; Forner, L.E.; Fuller, C.D.; Mowery, Y.M.; Murphy, B.A.; Watson, E.; et al. Prevention and management of osteoradionecrosis in patients with head and neck cancer treated with radiation therapy: ISOO–MASCC–ASCO guideline. J. Clin. Oncol. 2024, 42, 1975–1996.
- 112. Mohebbi, S.; Zabihidan, M.; Omidvari, A.; Abrishami, M. Post-COVID-19 maxillary bony sequestration: A case report on mucormycosis challenges. Clin. Case Rep. 2025, 13, e71080.
- 113. Lin, Z.C.; Bennett, M.H.; Hawkins, G.C.; Azzopardi, C.P.; Feldmeier, J.; Smee, R.; Milross, C. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database Syst. Rev. 2023, 8, CD005005.
- 114. Freiberger, J.J. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 2009, 67, 96–106.
- 115. Ruiz Rincón, M.; Cortés-Bretón Brinkmann, J.; Granić, M.; Sáez-Alcaide, L.M.; Sánchez-Labrador, L.; López-Carriches, C.; Madrigal Martínez-Pereda, C. Ozone therapy for medication-related osteonecrosis of the jaw: A scoping review. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2025.
- 116. Longo, F.; Guida, A.; Aversa, C.; Pavone, E.; Di Costanzo, G.; Ramaglia, L.; Ionna, F. Platelet rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw: Personal experience and review of the literature. Int. J. Dent. 2014, 2014, 298945.
- 117. Hanna, R.; Miron, I.C.; Dalvi, S.; Arany, P.; Bensadoun, R.J.; Benedicenti, S. A systematic review of laser photobiomodulation dosimetry and treatment protocols in the management of medication-related osteonecrosis of the jaws: A rationalised consensus for future randomized controlled clinical trials. Pharmaceuticals 2024, 17, 1011.
- 118. Urias-Barreras, C.M.; Rodríguez-Archilla, A.; Canizalez-Roman, A.; Bastidas, D.A.; León-Sicairos, N.M. Maxillary mucormycosis and aspergillosis in post-COVID-19 patients in Mexico: A case series. J. Stomatol. Oral Maxillofac. Surg. 2024, 125, 101615.
References
1. Kohansal Vajari, M.; Shirin, M.; Pourbagheri-Sigaroodi, A.; Akbari, M.E.; Abolghasemi, H.; Bashash, D. COVID-19-related coagulopathy: A review of pathophysiology and pharmaceutical management. Cell Biol. Int. 2021, 45, 1832–1850.
2. Conway, E.M.; Mackman, N.; Warren, R.Q.; Wolberg, A.S.; Mosnier, L.O.; Campbell, R.A.; Gralinski, L.E.; Rondina, M.T.; van de Veerdonk, F.L.; Hoffmeister, K.M.; et al. Understanding COVID-19-associated coagulopathy. Nat. Rev. Immunol. 2022, 22, 639–649.
3. Bobamuratova, D.; Boymuradov, S.; Kurbanov, Y. Complications in the maxillofacial region in patients with COVID-19. J. Neurol. Sci. 2021, 429, 119784.
4. Abdullah, B.; Museedi, O.; Allawi, N.; Ismael, F.J.; Warnakulasuriya, S. Impact of COVID-19 on the prevalence of oral and maxillofacial disorders: A retrospective cohort study. Sci. Prog. 2025, 108, 368504251326453.
5. Vardas, E.; Adamo, D.; Canfora, F.; Kouri, M.; Delli, K.; Mignogna, M.D.; Nikitakis, N. Impact of COVID-19 disease on the development of osteomyelitis of jaws: A systematic review. J. Clin. Med. 2024, 13, 4290.
6. Khan, M.A.; Rahman, T.; Rahman, S.A.; Hashmi, G.S.; Ansari, M.K.; Danish, M.; Arman, M.; Ahmad, R.; Ahmad, W. Is post-COVID osteonecrosis of jaw (PCONJ) masquerading as osteomyelitis? A largest unicentric report of 13 cases. Adv. Oral Maxillofac. Surg. 2023, 11, 100435.
7. Al-Mahalawy, H.; El-Mahallawy, Y.; Dessoky, N.Y.; Ibrahim, S.; Amer, H.; Ayad, H.M.; El Sherif, H.M.; Shabaan, A.A. Post-COVID-19 related osteonecrosis of the jaw (PC-RONJ): An alarming morbidity in COVID-19 surviving patients. BMC Infect. Dis. 2022, 22, 544.
8. Yfanti, Z.; Tetradis, S.; Nikitakis, N.G.; Alexiou, K.E.; Makris, N.; Angelopoulos, C.; Tsiklakis, K. Radiologic findings of osteonecrosis, osteoradionecrosis, osteomyelitis and jaw metastatic disease with cone beam CT. Eur. J. Radiol. 2023, 165, 110916.
9. Subramaniam, S.; Kothari, H.; Bosmann, M. Tissue factor in COVID-19-associated coagulopathy. Thromb. Res. 2022, 220, 35–47.
10. Mañón, V.A.; Balandran, S.; Young, S.; Wong, M.; Melville, J.C. COVID-associated avascular necrosis of the maxilla—A rare, new side effect of COVID-19. J. Oral Maxillofac. Surg. 2022, 80, 1254–1259.
11. Sourani, A.; Kalantari, F.; El-Rabbany, M.; Shahmoradi, M.; Haridas, A.; Vahdat, N.; Mirza, S.; Sourani, A.; Foroughi, M.; Baradaran Mahdavi, S. COVID-19 and jaw osteonecrosis: A systematic review on clinical presentations and treatment outcomes. Curr. Probl. Surg. 2025, 73, 101897.
12. Cheng, E.Y.; Mirzaei, A.; Sugano, N.; Hernigou, P.; Jones, L.C.; Koo, K.-H.; Drescher, W.R.; Cui, Q.; Sierra, R.J.; Goodman, S.B.; et al. Osteonecrosis: A more appropriate term than avascular necrosis—Pathophysiologic rationale. J. Arthroplast. 2025, 40, 2729–2736.
13. Lončar Brzak, B.; Horvat Aleksijević, L.; Vindiš, E.; Kordić, I.; Granić, M.; Vidović Juras, D.; Andabak Rogulj, A. Osteonecrosis of the jaw. Dent. J. 2023, 11, 23.
14. Tetradis, S.; Allen, M.R.; Ruggiero, S.L. Pathophysiology of medication-related osteonecrosis of the jaw—A minireview. JBMR Plus 2023, 7, e10785.
15. Hines, J.T.; Jo, W.-L.; Cui, Q.; Mont, M.A.; Koo, K.-H.; Cheng, E.Y.; Goodman, S.B.; Ha, Y.-C.; Hernigou, P.; Jones, L.C.; et al. Osteonecrosis of the femoral head: An updated review of ARCO on pathogenesis, staging and treatment. J. Korean Med. Sci. 2021, 36, e177. [
16. Ruggiero, S.L.; Dodson, T.B.; Aghaloo, T.; Carlson, E.R.; Ward, B.B.; Kademani, D. American Association of Oral and Maxillofacial Surgeons’ position paper on medication-related osteonecrosis of the jaws—2022 update. J. Oral Maxillofac. Surg. 2022, 80, 920–943.
17. Hakobyan, K.; Poghosyan, Y. “Krokodil” drug-related osteonecrosis of midface: A case series. J. Craniomaxillofac. Surg. 2019, 47, 1918–1921.
18. Sharma, S.; Shankar, R.; Ravi Kiran, B.S.; Breh, R.; Sarangi, S.; Kumar Upadhyay, A. A narrative review of osteonecrosis of the jaw: What a clinician should know. Cureus 2023, 15, e51183.
19. Singh, G.; Campos, A.; Guan, H. Medication-Related Osteonecrosis of the Jaw. 2009. Available online: https://radiopaedia.org/articles/medication-related-osteonecrosis-of-the-jaw?lang=us
20. Thomas, J.G.; Ouanounou, A. Medication-related osteonecrosis of the jaw: A narrative review of risk factors, diagnosis, and management. Front. Oral Maxillofac. Med. 2023, 5, 31.
21. Havndrup-Pedersen, C.; Møller Andersen, S.W.; Nyberg, J.; Kofod, T. New classification system for osteoradionecrosis of the jaws—An integrative review. Br. J. Oral Maxillofac. Surg. 2025, 63, 707–713.
22. Bolchis, V.; Alexa, I.; Toderas, N.A.; Dumitrescu, R.; Sava-Rosianu, R.; Balean, O.; Alexa, V.T.; Popescu, S.; Jumanca, D.; Galuscan, A.; et al. Associations between lifestyle factors, oral health behaviors, and glycemic control in type 2 diabetic patients. J. Clin. Med. 2025, 14, 450.
23. Oliver-Puigdomènech, C.; González-Navarro, B.; Polis-Yanes, C.; Estrugo-Devesa, A.; Jané-Salas, E.; López-López, J. Incidence rate of metastases in the oral cavity: A review of all metastatic lesions in the oral cavity. Med. Oral Patol. Oral Cir. Bucal 2021, 26, e619–e625.
24. Ruggiero, S.L.; Dodson, T.B.; Aghaloo, T.; Carlson, E.R.; Ward, B.B.; Kademani, D. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J. Oral Maxillofac. Surg. 2014, 72, 1938–1956.
25. Trimarchi, M.; Bertazzoni, G.; Bussi, M. Cocaine-induced midline destructive lesions. Rhinology 2014, 52, 104–111.
26. Lončar Brzak, B.; Vučičević Boras, V.; Kotarac Knežević, A.; Sušić, M.; Seiwerth, S.; Gabrić, D. Idiopathic exposed bone lesions of the jaw. Dent. J. 2019, 7, 55.
27. Bansal, H. Medication-related osteonecrosis of the jaw: An update. Natl. J. Maxillofac. Surg. 2022, 13, 5.
28. Khan, A.A.; Morrison, A.; Hanley, D.A.; Felsenberg, D.; McCauley, L.K.; O’Ryan, F.; Reid, I.R.; Ruggiero, S.L.; Taguchi, A.; Tetradis, S.; et al. Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus. J. Bone Miner. Res. 2015, 30, 3–23.
29. Moreno, A.C.; Watson, E.E.; Humbert-Vidan, L.; Peterson, D.E.; van Dijk, L.V.; Guerrero Urbano, T.; Van den Bosch, L.; Hope, A.J.; Katz, M.S.; Hoebers, F.J.P.; et al. International expert-based consensus definition, classification criteria, and minimum data elements for osteoradionecrosis of the jaw: An interdisciplinary modified Delphi study. Int. J. Radiat. Oncol. Biol. Phys. 2025, 122, 341–354.
30. Peckham, H.; de Gruijter, N.M.; Raine, C.; Radziszewska, A.; Ciurtin, C.; Wedderburn, L.R.; Rosser, E.C.; Webb, K.; Deakin, C.T. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat. Commun. 2020, 11, 6317.
31. Pai, V.; Sansi, R.; Kharche, R.; Bandili, S.C.; Pai, B. Rhino-orbito-cerebral mucormycosis: Pictorial review. Insights Imaging 2021, 12, 167.
32. Justine, D.; Bhalla, A.S.; Manchanda, S.; Bhutia, O.; Roychoudhury, A. Osteomyelitis of the jaw bones and its mimics: Resolving the diagnostic enigma. Indian J. Radiol. Imaging 2025, 35, 361–373.
33. Said Ahmed, W.M.; Elsherbini, A.M.; Elsherbiny, N.M.; El-Sherbiny, M.; Ramzy, N.I.; Arafa, A.F. Maxillary mucormycosis osteomyelitis in post COVID-19 patients: A series of fourteen cases. Diagnostics 2021, 11, 2050.
34. Yasir, M.; Goyal, A.; Sonthalia, S. Corticosteroid Adverse Effects. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2026. Available online: https://www.ncbi.nlm.nih.gov/books/NBK531462/
35. Amaral, T.F.d.; Coutinho, N.M.d.S.R.; Fuentefria, R.d.N.; Fuentefria, A.M.; Machado, G.d.R.M. Corticosteroid therapy associated with COVID-19: An ally or a risk factor for the establishment of secondary fungal co-infections? Clin. Biomed. Res. 2023, 42, 369–377.
36. RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N. Engl. J. Med. 2021, 384, 693–704.
37. Wang, A.S.; Armstrong, E.J.; Armstrong, A.W. Corticosteroids and wound healing: Clinical considerations in the perioperative period. Am. J. Surg. 2013, 206, 410–417.
38. Gupta, A.; Kayarat, B.; Gupta, N. COVID-19 associated mucormycosis (CAM). Saudi J. Anaesth. 2023, 17, 58–64.
39. Liu, L.H.; Zhang, Q.Y.; Sun, W.; Li, Z.R.; Gao, F.Q. Corticosteroid-induced osteonecrosis of the femoral head. Chin. Med. J. 2017, 130, 2601–2607.
40. Mantovani, A.; Byrne, C.D.; Zheng, M.H.; Targher, G. Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. Nutr. Metab. Cardiovasc. Dis. 2020, 30, 1236–1248.
41. Hoenigl, M.; Seidel, D.; Carvalho, A.; Rudramurthy, S.M.; Arastehfar, A.; Gangneux, J.-P.; Nasir, N.; Bonifaz, A.; Araiza, J.; Klimko, N.; et al. The emergence of COVID-19 associated mucormycosis: A review of cases from 18 countries. Lancet Microbe 2022, 3, e543–e552.
42. Ibrahim, A.S.; Spellberg, B.; Walsh, T.J.; Kontoyiannis, D.P. Pathogenesis of mucormycosis. Clin. Infect. Dis. 2012, 54, S16–S22.
43. Pal, R.; Singh, B.; Bhadada, S.K.; Banerjee, M.; Bhogal, R.S.; Hage, N.; Kumar, A. COVID-19-associated mucormycosis: An updated systematic review of literature. Mycoses 2021, 64, 1452–1459.
44. Rao, V.U.S.; Arakeri, G.; Madikeri, G.; Shah, A.; Oeppen, R.S.; Brennan, P.A. COVID-19 associated mucormycosis (CAM) in India: A formidable challenge. Br. J. Oral Maxillofac. Surg. 2021, 59, 1095–1098.
45. Ackermann, M.; Verleden, S.E.; Kuehnel, M.; Haverich, A.; Welte, T.; Laenger, F.; Vanstapel, A.; Werlein, C.; Stark, H.; Tzankov, A.; et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N. Engl. J. Med. 2020, 383, 120–128.
46. Ghanbari, E.P.; Jakobs, K.; Puccini, M.; Reinshagen, L.; Friebel, J.; Haghikia, A.; Kränkel, N.; Landmesser, U.; Rauch-Kröhner, U. The role of NETosis and complement activation in COVID-19-associated coagulopathies. Biomedicines 2023, 11, 1371.
47. Perico, L.; Morigi, M.; Galbusera, M.; Pezzotta, A.; Gastoldi, S.; Imberti, B.; Perna, A.; Ruggenenti, P.; Donadelli, R.; Benigni, A.; et al. SARS-CoV-2 spike protein 1 activates microvascular endothelial cells and complement system leading to platelet aggregation. Front. Immunol. 2022, 13, 827146.
48. Yamaoka-Tojo, M. Endothelial glycocalyx damage as a systemic inflammatory microvascular endotheliopathy in COVID-19. Biomed. J. 2020, 43, 399–413.
49. Song, J.; Li, Y.; Huang, X.; Chen, Z.; Li, Y.; Liu, C.; Chen, Z.; Duan, X. Systematic analysis of ACE2 and TMPRSS2 expression in salivary glands reveals underlying transmission mechanism caused by SARS-CoV-2. J. Med. Virol. 2020, 92, 2556–2566.
50. Xu, S.; Ilyas, I.; Weng, J. Endothelial dysfunction in COVID-19: An overview of evidence, biomarkers, mechanisms and potential therapies. Acta Pharmacol. Sin. 2023, 44, 695–709.
51. Daher, J. Endothelial dysfunction and COVID-19 (Review). Biomed. Rep. 2021, 15, 102.
52. Lin, E.-C.; Chiang, Y.-C.; Lin, H.-Y.; Tseng, S.-Y.; Hsieh, Y.-T.; Shieh, J.-A.; Huang, Y.-H.; Tsai, H.-T.; Feng, S.-W.; Peng, T.-Y.; et al. Unraveling the link between periodontitis and coronavirus disease 2019: Exploring pathogenic pathways and clinical implications. Biomedicines 2023, 11, 2789.
53. Qi, X.; Northridge, M.E.; Hu, M.; Wu, B. Oral health conditions and COVID-19: A systematic review and meta-analysis of the current evidence. Aging Health Res. 2022, 2, 100064.
54. Huang, N.; Pérez, P.; Kato, T.; Mikami, Y.; Okuda, K.; Gilmore, R.C.; Domínguez Conde, C.; Gasmi, B.; Stein, S.; Beach, M.; et al. SARS-CoV-2 infection of the oral cavity and saliva. Nat. Med. 2021, 27, 892–903.
55. Alahdal, M.; Elkord, E. Exhaustion and over-activation of immune cells in COVID-19: Challenges and therapeutic opportunities. Clin. Immunol. 2022, 245, 109177.
56. Gustine, J.N.; Jones, D. Immunopathology of hyperinflammation in COVID-19. Am. J. Pathol. 2021, 191, 4–17.
57. Chen, Z.; Wherry, E.J. T cell responses in patients with COVID-19. Nat. Rev. Immunol. 2020, 20, 529–536.
58. Zhang, S.; Asquith, B.; Szydlo, R.; Tregoning, J.S.; Pollock, K.M. Peripheral T cell lymphopenia in COVID-19: Potential mechanisms and impact. Immunother. Adv. 2021, 1, ltab015.
59. Ronchetti, S.; Ricci, E.; Migliorati, G.; Gentili, M.; Riccardi, C. How glucocorticoids affect the neutrophil life. Int. J. Mol. Sci. 2018, 19, 4090.
60. Ibrahim, A.S. Host cell invasion in mucormycosis: Role of iron. Curr. Opin. Microbiol. 2011, 14, 406–411.
61. Arora, U.; Priyadarshi, M.; Katiyar, V.; Soneja, M.; Garg, P.; Gupta, I.; Bharadiya, V.; Berry, P.; Ghosh, T.; Patel, L.; et al. Risk factors for coronavirus disease-associated mucormycosis. J. Infect. 2022, 84, 383–390.
62. Bhanuprasad, K.; Manesh, A.; Devasagayam, E.; Varghese, L.; Cherian, L.M.; Kurien, R.; Karthik, R.; Deodhar, D.; Vanjare, H.; Peter, J.; et al. Risk factors associated with the mucormycosis epidemic during the COVID-19 pandemic. Int. J. Infect. Dis. 2021, 111, 267–270
63. Hernández, J.L.; Buckley, C.J. Mucormycosis. In StatPearls; StatPearls Publishing: Treasure Island, FL, USA, 2025. Available online: https://www.ncbi.nlm.nih.gov/books/NBK544364/
64. Jeican, I.I.; Horhat, D.I.; Dumitru, M.; Florea, A.; Barbu-Tudoran, L.; Gheban, B.-A.; Anton, V.; Toader, C.; Aluaș, M.; Siserman, C.V.; et al. COVID-19-associated rhino-orbital mucormycosis: Histological and electron microscopy characteristics. Diagnostics 2024, 14, 429.
65. Domán, M.; Bányai, K. COVID-19-associated fungal infections: An urgent need for alternative therapeutic approach? Front. Microbiol. 2022, 13, 919501.
66. Fakhar, M.; Zakariaei, Z.; Sharifpour, A.; Banimostafavi, E.S.; Pourmousa, R.; Soleymani, M.; Ghasemi, M. Post-COVID-19 maxillary osteonecrosis and floating maxillary teeth due to mucormycosis in two uncontrolled diabetic patients. Clin. Case Rep. 2022, 10, e05502.
67. Kang, Y.-H.; Lee, S.-S.; Aung, M.T.Z.; Kang, J.-H.; Kim, J.-E.; Huh, K.-H.; Heo, M.-S. Mucormycosis-related osteomyelitis of the maxilla in a post-COVID-19 patient. Imaging Sci. Dent. 2022, 52, 435.
68. Motevasseli, S.; Nazarpour, A.; Dalili Kajan, Z.; Yousefi, Z.; Khosravifard, N.; Kashi, F.; Roudbari, N. Post-COVID mucormycosis osteomyelitis and its imaging manifestations in the north of Iran: Case series. Oral Radiol. 2024, 40, 69–80.
69. Weinstein, R.S. Glucocorticoid-induced osteonecrosis. Endocrine 2012, 41, 183–190.
70. Xie, X.H.; Wang, X.L.; Yang, H.L.; Zhao, D.W.; Qin, L. Steroid-associated osteonecrosis: Epidemiology, pathophysiology, animal model, prevention, and potential treatments. J. Orthop. Transl. 2015, 3, 58–70.
71. Powell, C.; Chang, C.; Naguwa, S.M.; Cheema, G.; Gershwin, M.E. Steroid-induced osteonecrosis: An analysis of steroid dosing risk. Autoimmun. Rev. 2010, 9, 721–743.
72. Zhang, Q.; Lv, J.; Jin, L. Role of coagulopathy in glucocorticoid-induced osteonecrosis of the femoral head. J. Int. Med. Res. 2018, 46, 2141–2148.
73. Rhou, Y.J.J.; Hor, A.; Wang, M.; Wu, Y.F.; Jose, S.; Chipps, D.R.; Cheung, N.W. Dexamethasone-induced hyperglycaemia in COVID-19: Glycaemic profile in patients without diabetes and factors associated with hyperglycaemia. Diabetes Res. Clin. Pract. 2022, 194, 110151.
74. Hwang, J.L.; Weiss, R.E. Steroid-induced diabetes: A clinical and molecular approach to understanding and treatment. Diabetes Metab. Res. Rev. 2014, 30, 96–102.
75. Barker, H.L.; Morrison, D.; Llano, A.; Sainsbury, C.A.R.; Jones, G.C. Practical guide to glucocorticoid-induced hyperglycaemia and diabetes. Diabetes Ther. 2023, 14, 937–945.
76. Spampinato, S.F.; Caruso, G.I.; De Pasquale, R.; Sortino, M.A.; Merlo, S. The treatment of impaired wound healing in diabetes: Looking among old drugs. Pharmaceuticals 2020, 13, 60.
77. Goulding, N.J.; Euzger, H.S.; Butt, S.K.; Perretti, M. Novel pathways for glucocorticoid effects on neutrophils in chronic inflammation. Inflamm. Res. 1998, 47, 158–165.
78. Narazaki, M.; Kishimoto, T. The two-faced cytokine IL-6 in host defense and diseases. Int. J. Mol. Sci. 2018, 19, 3528.
79. McElvaney, O.J.; Curley, G.F.; Rose-John, S.; McElvaney, N.G. Interleukin-6: Obstacles to targeting a complex cytokine in critical illness. Lancet Respir. Med. 2021, 9, 643–654.
80. The WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group.Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19. JAMA 2021, 326, 499.
81. Malgie, J.; Schoones, J.W.; Zeegers, M.P.; Pijls, B.G. Decreased mortality and increased side effects in COVID-19 patients treated with IL-6 receptor antagonists: Systematic review and meta-analysis. Sci. Rep. 2021, 11, 21522.
82. Roudbary, M.; Kumar, S.; Kumar, A.; Černáková, L.; Nikoomanesh, F.; Rodrigues, C.F. Overview on the prevalence of fungal infections, immune response, and microbiome role in COVID-19 patients. J. Fungi 2021, 7, 720.
83. Nambiar, M.; Varma, S.R.; Jaber, M.; Sreelatha, S.V.; Thomas, B.; Nair, A.S. Mycotic infections—Mucormycosis and oral candidiasis associated with COVID-19: A significant and challenging association. J. Oral Microbiol. 2021, 13, 1967699.
84. Aliberti, A.; Gasparro, R.; Mignogna, M.; Canfora, F.; Spagnuolo, G.; Sammartino, G.; Coppola, N. Unveiling the oral lesions, dysgeusia and osteonecrosis related to COVID-19: A comprehensive systematic review. J. Clin. Med. 2025, 14, 1267.
85. Grillo, R.; Samiei Rad, S.; Alizadeh, O.; Hosseini Zarch, S.H.; Khodashahi, R.; Kazemian, N.; Naclério-Homem, M.G. Two cases of COVID-related osteonecrosis of the jaws: A new and worrying entity is emerging. World J. Plast. Surg. 2024, 13, 96–102.
86. Bansal, P.; Goyal, A.; Cusick, A.; Lahan, S.; Dhaliwal, H.S.; Bhyan, P.; Bhattad, P.B.; Aslam, F.; Ranka, S.; Dalia, T.; et al. Hydroxychloroquine: A comprehensive review and its controversial role in coronavirus disease 2019. Ann. Med. 2021, 53, 117–134.
87. Ponnaiah, M.; Ganesan, S.; Bhatnagar, T.; Thulasingam, M.; Majella, M.G.; Karuppiah, M.; Rizwan, S.A.; Alexander, A.; Sarkar, S.; Kar, S.S.; et al. Hyperglycemia and steroid use increase the risk of rhino-orbito-cerebral mucormycosis regardless of COVID-19 hospitalization: Case-control study, India. PLoS ONE 2022, 17, e0272042.
88. Espi, M.; Koppe, L.; Fouque, D.; Thaunat, O. Chronic kidney disease-associated immune dysfunctions: Impact of protein-bound uremic retention solutes on immune cells. Toxins 2020, 12, 300.
89. Syed-Ahmed, M.; Narayanan, M. Immune dysfunction and risk of infection in chronic kidney disease. Adv. Chronic Kidney Dis. 2019, 26, 8–15.
90. Portolés, J.; Martín, L.; Broseta, J.J.; Cases, A. Anemia in chronic kidney disease: From pathophysiology and current treatments to future agents. Front. Med. 2021, 8, 642296.
91. Badura, K.; Janc, J.; Wąsik, J.; Gnitecki, S.; Skwira, S.; Młynarska, E.; Rysz, J.; Franczyk, B. Anemia of chronic kidney disease—A narrative review of its pathophysiology, diagnosis, and management. Biomedicines 2024, 12, 1191.
92. Palit, S.; Kendrick, J. Vascular calcification in chronic kidney disease: Role of disordered mineral metabolism. Curr. Pharm. Des. 2014, 20, 5829–5833.
93. Aguilar, A.; Gifre, L.; Ureña-Torres, P.; Carrillo-López, N.; Rodriguez-García, M.; Massó, E.; da Silva, I.; López-Báez, V.; Sánchez-Bayá, M.; Prior-Español, Á.; et al. Pathophysiology of bone disease in chronic kidney disease: From basics to renal osteodystrophy and osteoporosis. Front. Physiol. 2023, 14, 1177829.
94. Lafage-Proust, M.H. Bone and chronic kidney disease. Semin. Musculoskelet. Radiol. 2023, 27, 463–470.
95. Goel, K.; Dhillon, J.; Yadav, V.; Bhagat, S.; Aggarwal, A. Post-COVID isolated mandibular mucormycosis in a patient with chronic kidney disease: A case report. Indian J. Otolaryngol. Head Neck Surg. 2023, 75, 2538–2543.
96. van Cann, T.; Loyson, T.; Verbiest, A.; Clement, P.M.; Bechter, O.; Willems, L.; Spriet, I.; Coropciuc, R.; Politis, C.; Vandeweyer, R.O.; et al. Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support. Care Cancer 2018, 26, 869–878.
97. Bobamuratova, D.T.; Boymuradov, S.A.; Dar-Odeh, N.S.; Kurbanov, Y.K.; Umarov, R.Z. Impact of COVID-19 disease and its treatment on the development of maxillofacial complications. Adv. Oral Maxillofac. Surg. 2021, 4, 100169.
98. Dar-Odeh, N.; Bobamuratova, D.T.; Alnazzawi, A.; Babkair, H.; Jambi, S.; Abu-Hammad, A.; Abu-Hammad, O. Jaw-related complications in COVID-19 patients: A systematic review. CRANIO 2024, 42, 630–637.
99. Kaboosaya, B.; Damrongsirirat, N.; Koosrivinij, S.; Pimkhaokham, A. Invasive Maxillary Mucormycosis in Post-COVID-19: A Case Report and Review of Literatures. J. Dent. Assoc. Thai. 2024, 74, 108–122.
100. Datarkar, A.; Bhawalkar, A.; Shah, V.; Manekar, V.; Gadve, V.; Daware, S.; Walkey, D.; Gioia, F.; Acero, J. Osteomyelitis of the jaw due to mucormycosis after coronavirus disease 2019 infection—A prospective study. Ann. Maxillofac. Surg. 2024, 14, 40–45.
101. Vijapur, M.; Kattimani, V.; Varsha, V.; Girish, H.; Kamat, M.; Ram, B. COVID-19 associated mucormycosis (CAM): A single hospital-based study. J. Oral Maxillofac. Pathol. 2022, 26, 147–155.
102. Altay, M.A.; Eroğlu, C.N.; Karaca, B.; Doğan, S.U. Post-COVID-19 extensive maxillary actinomycotic osteonecrosis: A rare case report. Akdeniz Diş Hekim. Derg. 2025, 4, 63–69.
103. Omranzadeh, A.; Afzalzadeh, M.; Ghodsi, A.; Neshati, H.; Mahdavi Rashed, M. Radiological features of COVID-19-associated mucormycosis: A report of 36 cases along with a literature review. Clin. Case Rep. 2023, 11, e8154.
104. Romano, A.; Gasparro, R.; Campana, M.D.; Pinchera, B.; Di Crescenzo, R.M.; Del Guercio, D.; Sarcinella, M.; Tatullo, M.; Sammartino, G. COVID-19 as a critical risk factor for osteonecrosis of the jaw: Diagnostic challenge and surgical treatment. Curr. Probl. Surg. 2024, 61, 101555.
105. Rudramurthy, S.M.; Hoenigl, M.; Meis, J.F.; Cornely, O.A.; Muthu, V.; Gangneux, J.P.; Perfect, J.; Chakrabarti, A. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses 2021, 64, 1028–1037.
106. Cornely, O.A.; Alastruey-Izquierdo, A.; Arenz, D.; Chen, S.C.A.; Dannaoui, E.; Hochhegger, B.; Hoenigl, M.; Jensen, H.E.; Lagrou, K.; Lewis, R.E.; et al. Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect. Dis. 2019, 19, e405–e421.
107. Muthu, V.; Agarwal, R.; Patel, A.; Kathirvel, S.; Abraham, O.C.; Aggarwal, A.N.; Bal, A.; Bhalla, A.S.; Chhajed, P.N.; Chaudhry, D.; et al. Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India. Lancet Infect. Dis. 2022, 22, e240–e253.
108. Huynh, D.V.; Nguyen, D.K.; Nguyen, T.V.; Bui, T.V.; Le, C.T. Maxillary osteonecrosis related to post-COVID-19: A report of case series and 6-month follow-up. J. Oral Maxillofac. Surg. Med. Pathol. 2025, 37, 180–187.
109. Gaêta-Araujo, H.; Vanderhaeghen, O.; Vasconcelos, K.F.; Coucke, W.; Coropciuc, R.; Politis, C.; Jacobs, R. Osteomyelitis, osteoradionecrosis, or medication-related osteonecrosis of the jaws? Can CBCT enhance radiographic diagnosis? Oral Dis. 2021, 27, 312–319.
110. Yasmin, F.; Najeeb, H.; Naeem, A.; Dapke, K.; Phadke, R.; Asghar, M.S.; Shah, S.M.I.; De Berardis, D.; Ullah, I. COVID-19 associated mucormycosis: A systematic review from diagnostic challenges to management. Diseases 2021, 9, 65
111. Peterson, D.E.; Koyfman, S.A.; Yarom, N.; Lynggaard, C.D.; Ismaila, N.; Forner, L.E.; Fuller, C.D.; Mowery, Y.M.; Murphy, B.A.; Watson, E.; et al. Prevention and management of osteoradionecrosis in patients with head and neck cancer treated with radiation therapy: ISOO–MASCC–ASCO guideline. J. Clin. Oncol. 2024, 42, 1975–1996.
112. Mohebbi, S.; Zabihidan, M.; Omidvari, A.; Abrishami, M. Post-COVID-19 maxillary bony sequestration: A case report on mucormycosis challenges. Clin. Case Rep. 2025, 13, e71080.
113. Lin, Z.C.; Bennett, M.H.; Hawkins, G.C.; Azzopardi, C.P.; Feldmeier, J.; Smee, R.; Milross, C. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database Syst. Rev. 2023, 8, CD005005.
114. Freiberger, J.J. Utility of hyperbaric oxygen in treatment of bisphosphonate-related osteonecrosis of the jaws. J. Oral Maxillofac. Surg. 2009, 67, 96–106.
115. Ruiz Rincón, M.; Cortés-Bretón Brinkmann, J.; Granić, M.; Sáez-Alcaide, L.M.; Sánchez-Labrador, L.; López-Carriches, C.; Madrigal Martínez-Pereda, C. Ozone therapy for medication-related osteonecrosis of the jaw: A scoping review. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2025.
116. Longo, F.; Guida, A.; Aversa, C.; Pavone, E.; Di Costanzo, G.; Ramaglia, L.; Ionna, F. Platelet rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw: Personal experience and review of the literature. Int. J. Dent. 2014, 2014, 298945.
117. Hanna, R.; Miron, I.C.; Dalvi, S.; Arany, P.; Bensadoun, R.J.; Benedicenti, S. A systematic review of laser photobiomodulation dosimetry and treatment protocols in the management of medication-related osteonecrosis of the jaws: A rationalised consensus for future randomized controlled clinical trials. Pharmaceuticals 2024, 17, 1011.
118. Urias-Barreras, C.M.; Rodríguez-Archilla, A.; Canizalez-Roman, A.; Bastidas, D.A.; León-Sicairos, N.M. Maxillary mucormycosis and aspergillosis in post-COVID-19 patients in Mexico: A case series. J. Stomatol. Oral Maxillofac. Surg. 2024, 125, 101615.